New York State Teachers Retirement System Cuts Position in Lantheus Holdings, Inc. $LNTH

New York State Teachers Retirement System lowered its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.0% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 83,612 shares of the medical equipment provider’s stock after selling 856 shares during the quarter. New York State Teachers Retirement System owned about 0.12% of Lantheus worth $6,844,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of LNTH. State of Michigan Retirement System boosted its position in shares of Lantheus by 0.6% in the first quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider’s stock worth $1,620,000 after buying an additional 100 shares during the period. Signaturefd LLC increased its position in shares of Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 116 shares during the last quarter. Intrust Bank NA lifted its stake in shares of Lantheus by 2.9% in the first quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider’s stock worth $431,000 after acquiring an additional 125 shares in the last quarter. Focus Financial Network Inc. boosted its holdings in Lantheus by 4.0% in the second quarter. Focus Financial Network Inc. now owns 3,576 shares of the medical equipment provider’s stock valued at $293,000 after purchasing an additional 136 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in Lantheus by 2.1% during the 1st quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider’s stock valued at $653,000 after purchasing an additional 139 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on LNTH shares. William Blair reiterated a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. B. Riley decreased their price objective on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, September 16th. TD Cowen cut their target price on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, September 15th. Weiss Ratings restated a “hold (c-)” rating on shares of Lantheus in a research note on Wednesday, October 8th. Finally, Mizuho dropped their price objective on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, August 7th. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $74.50.

Insider Activity

In related news, insider Rajiv A. Patel sold 3,365,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider directly owned 3,477,227 shares in the company, valued at $195,246,296.05. The trade was a 49.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the sale, the insider directly owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,812,000 shares of company stock worth $382,427,380. 2.00% of the stock is owned by company insiders.

Lantheus Trading Down 1.3%

Lantheus stock opened at $55.60 on Monday. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $118.21. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07. The stock has a market capitalization of $3.78 billion, a PE ratio of 14.79 and a beta of 0.09. The firm has a 50 day simple moving average of $53.91 and a 200-day simple moving average of $72.96.

Lantheus (NASDAQ:LNTH) last released its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The firm had revenue of $92.51 million during the quarter. As a group, equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.